Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Instagram Outage Disrupts Thousands of U.S. Users 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
STAMFORD, Conn., March 01, 2017 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview at the Cowen and Company 37th Annual Health Care Conference in Boston on Wednesday, March 8, 2017 at 10:40AM Eastern Time.
A live broadcast of the presentation will be available at http://ir.loxooncology.com/. An archived replay of the presentation will be available on the company’s website for 30 days following the presentation.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]
Media:
Dan Budwick
Pure Communications
973-271-6085
[email protected]
